Investigational Drug Details
| Drug ID: | D016 |
| Drug Name: | Methionine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00134 |
| DrugBank Description: | A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. |
| PubChem ID: | 6137 |
| CasNo: | 63-68-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CSCC[C@H](N)C(O)=O |
| Structure: |
|
| InChiKey: | FFEARJCKVFRZRR-BYPYZUCNSA-N |
| Molecular Weight: | 149.211 |
| DrugBank Targets: | Methionine synthase reductase; Methionine synthase; Methionine aminopeptidase 2; Betaine--homocysteine S-methyltransferase 1; S-methylmethionine--homocysteine S-methyltransferase BHMT2 |
| DrugBank MoA: | The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. |
| DrugBank Pharmacology: | L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity. |
| DrugBank Indication: | Used for protein synthesis including the formation of SAMe, L-homocysteine, L-cysteine, taurine, and sulfate. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1088 | NCT00244530 | PHASE4 | COMPLETED | NO | 2001-06 | 2006-12-22 | Details |
| L6268 | NCT01919788 | COMPLETED | NO | 2013-08 | 2019-09-27 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00053 | 1314826 | J Biol Chem | Substitution of isoleucine for methionine at position 1153 in the beta-subunit of the human insulin receptor. A mutation that impairs receptor tyrosine kinase activity, receptor endocytosis, and insulin action. | Details |
| A00117 | 1890161 | J Clin Endocrinol Metab | A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman. | Details |